Neurotech's vision loss cell therapy implant hits primary goals in phase 3 trials

A pair of phase 3 trials of Neurotech Pharmaceuticals’ encapsulated cell therapy implant have met their primary endpoints, positioning the biotech to talk to the FDA about bringing the treatment for a cause of central vision loss to market.